Pharmaceutical industry celebrates in markets the victory of Republican Donald Trump. But above all, investors applause the beat of Hillary Clinton's Democrat, the candidate who promised to condense the tall costs of drugs in the country..
In the terse term, companies do not foresee major decisions upon the Republican agenda that may achievement the sector..
The best example of what Clinton believed abused laboratories was the skirmish of Mylan taking into consideration his drug EpiPen next to anaphylactic shocks.This product multiplied by six its price in five years, to attain 600 dollars, which entailed a embassy response in recent weeks to manage a entirely deregulated pharmaceutical market.
De Trump, however, is not normal to understand such measures. That has prompted companies to recover from a drop that began last year, considering Clinton has already threatened to direct the prices of expensive militant treatments. The Democrat wanted mechanisms to oversee transparency in pricing decisions.
Investors had previously discounted roughly 30% of the amassing prices of laboratories, especially biotechnology. In the last two days, the Bloomberg World Pharmaceutical Index - index that reflects the development of the largest companies in the sector - has revalued 5% and in the Bloomberg World Biotechnological Index the recovery has been even greater, of 8.5%.
"Health care companies would have been worse off once Clinton, who warned, greater than the last few months, of the price of medicines," says Victoria Torres, analyst at Selfbank. "Our Grifols could be one of the beneficiaries in this case, in imitation of that it obtains in the US more than 60% of its income," he adds.
"Trump's victory should be determined for the healthcare sector. Pharmaceuticals have been under muggy pressure because of the threat that a certain Democratic victory would create it viable to pass laws that would allow the executive to interfere and repair drug prices, and now, after this risk has disappeared, they should recover.
#p# " Says Matt Siddle, equity fund executive for Fidelity. "The values of this sector have yielded considerable pitch and I am still conveniently betting upon them next to degrade setting businesses in areas past similar characteristics to the bonds, such as public services and telecommunications," he adds. #p#
It is precisely the biopharmaceuticals that recover the most, furthermore because they were the ones that had suffered the most past January. Celgene recovered more than 11% in the last two days, Allergan in the vicinity of 9%, Amgen above 8% and Gilead in relation to 7%.
behind regard to large American farms, Pfizer recovers 10%, in the engagement of MSD 8%, Bristol-Myers Squibb more than 7% and Lilly choice 7%.
along with the European ones, Roche, Sanofi and Novartis rise above 4%.
The victory of Donald Trump along with has a forward membership in the Spanish listed companies of the biopharmaceutical sector, before all have recovered positions in hoard argument in the last two sessions.
The motives are the similar as in the clash of global companies: the threat of cutbacks in drug prices proposed by Democrat Hillary Clinton is touching away.
how do you become a pharmaceutical rep
How to get into pharmaceutical sales without experience
The pharmacist, (acting as sales representative), should realize that their task isn't to obtain sales unnaturally or forced, but bringing products and services to people that actually can help.